

(19) AUSTRALIAN PATENT OFFICE

(54) Title
Dihydroimidazo[4,5-e]indole and 7H-pyrrolo[3,2-f]quinoxaline derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands

(51)⁶ International Patent Classification(s)

C07D 519/00	3/04		
(2006.01)	20060101ALI2005122		
A61K 31/439	0BMJP	A61P	
(2006.01)	5/24		
A61K 31/4985	20060101ALI2005122		
(2006.01)	0BMJP	A61P	
A61P 1/04 (2006.01)	15/00		
A61P 1/08 (2006.01)	20060101ALI2005122		
A61P 1/14 (2006.01)	0BMJP	A61P	
A61P 3/04 (2006.01)	21/04		
A61P 5/24 (2006.01)	20060101ALI2005122		
A61P 15/00 (2006.01)	0BMJP	A61P	
A61P 21/04 (2006.01)	25/00		
A61P 25/00 (2006.01)	20060101ALI2006052		
A61P 25/06 (2006.01)	1BMDE	A61P	
A61P 25/06 (2006.01)	25/06		
A61P 25/14 (2006.01)	20060101ALI2005122		
A61P 25/16 (2006.01)	0BMJP	A61P	
A61P 25/18 (2006.01)	25/14		
A61P 25/22 (2006.01)	20060101ALI2005122		
A61P 25/24 (2006.01)	0BMJP	A61P	
A61P 25/28 (2006.01)	25/16		
A61P 25/30 (2006.01)	20060101ALI2005122		
A61P 43/00 (2006.01)	0BMJP	A61P	
C07D 519/00	25/18		
20060101AFI2005100	20060101ALI2005122		
8BMEP	A61K	0BMJP	A61P
31/439		25/22	
20060101ALI2005122		20060101ALI2005122	
0BMJP	A61K	0BMJP	A61P
31/4985		25/24	
20060101ALI2005122		20060101ALI2005122	
0BMJP	A61P	0BMJP	A61P
1/04		25/28	
20060101ALI2005122		20060101ALI2005122	
0BMJP	A61P	0BMJP	A61P
1/08		25/30	
20060101ALI2005122		20060101ALI2005122	
0BMJP	A61P	0BMJP	A61P
1/14		43/00	
20060101ALI2005122		20060101ALI2005122	
0BMJP	A61P	0BMJP	
		PCT/EP02/03582	

(21) Application No: 2002310904

(22) Application Date: 2002.03.30

(87) WIPO No: W002/088143

(30) Priority Data

(31) Number (32) Date (33) Country
101 21 215.1 2001.04.30 DE

(43) Publication Date: 2002.11.11

(43) Publication Journal Date: 2003.04.17

(71) Applicant(s)

Merck Patent GmbH

(72) Inventor(s)

Leibrock, Joachim, Schiemann, Kai, Bottcher, Henning

(74) Agent/Attorney

Davies Collison Cave, 255 Elizabeth Street, Sydney, NSW, 2000

(56) Related Art

CAS Registry Number 59156-95-5

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 November 2002 (07.11.2002)

PCT

(10) International Publication Number
WO 02/088143 A3

(51) International Patent Classification²: C07D 519/00, A61K 31/4985, 31/4188, A61P 25/00 // (C07D 519/00, 487:00, 453:00)

(21) International Application Number: PCT/EP02/03582

(22) International Filing Date: 30 March 2002 (30.03.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
101 21 215.1 30 April 2001 (30.04.2001) DE

(71) Applicant (for all designated States except US): MERCK PATENT GMBH [DE/DE]; Frankfurter Strasse 250, 64293 Darmstadt (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SCHIEMANN, Kai [DE/DE]; Mühlalstrasse 50, 64297 Darmstadt (DE); BÖTTCHER, Henning [DE/DE]; Stiftstrasse 12, 64287 Darmstadt (DE); LEIBROCK, Joachim [DE/DE]; Mühlstrasse 91A, 64313 Pfungstadt (DE).

(74) Common Representative: MERCK PATENT GMBH; Frankfurter Strasse 250, 64293 Darmstadt (DE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BJ, BI, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:

23 January 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DIHYDROIMIDAZO[4,5-E]INDOLE AND 7H PYRROLO[3,2-F]QUINOXALINE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND/OR SEROTONERGIC LIGANDS




(57) Abstract: Compounds of the formula (I) in which R¹, R², R³ and R⁴ are as defined in Claim 1, are ligands of the nicotinic acetylcholine receptor and/or serotonergic ligands and are suitable for the prophylaxis or treatment of psychoses, schizophrenia, depression, anxiety states, dementia, in particular Alzheimer's disease and Lewy bodies dementia, neurodegenerative disorders, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, Tourette's syndrome, learning and memory restrictions, bulimia, anorexia nervosa or other eating disorders, compulsive behaviour, premenstrual syndrome, age-induced memory impairment, amelioration of withdrawal symptoms in nicotine dependence, Strokes or brain damage by toxic compounds, and for the treatment of disorders which are characterised by an excess of circulating serotonin or by serotonergic hyperactivity.

WO 02/088143 A3

Dihydroimidazo[4,5-e]indole and 7H-pyrrolo[3,2-f]quinoxaline derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands

5 The invention relates to dihydroimidazo[4,5-e]indole and 7H-pyrrolo-[3,2-f]quinoxaline derivatives of the formula I

10



in which


A-B-D	is $-NR^6-CR^2=N-$, $-N=CR^2-NR^6-$ or $-N=CR^7-CR^8=N-$,
R^1	is H or Het ¹ ,
R^2	is H, A, cycloalkyl, $-(CH_2)_n-N(R^5)_2$, $-(CH_2)_n-OR^5$, $-(CH_2)_n-Ar$ or $-(CH_2)_n-Het$,
R^3	is H, Hal, OH, OA or $O-(CH_2)_n-Ar$,
R^4	is H, A or $-(CH_2)_n-Ar$,
R^5	is H or A,
R^6 , R^7 and R^8	are each, independently of one another, H, A or $-(CH_2)_n-Ar$,
R^7 and R^8	together are alternatively alkylene having from 3 to 6 carbon atoms,
A	is a linear or branched alkyl group having from 1 to 10 carbon atoms,
Ar	is phenyl, naphthyl or biphenyl, each of which is unsubstituted or monosubstituted or polysubstituted by Hal, A, OR ⁵ , N(R ⁵) ₂ , NO ₂ , CN, COOR ⁵ , CON(R ⁵) ₂ , NR ⁵ COR ⁵ , NR ⁵ CON(R ⁵) ₂ , NR ⁵ SO ₂ A, COR ⁵ , SO ₂ NR ⁵ or S(O) _m A,
cycloalkyl	is cycloalkyl having from 3 to 10 carbon atoms,
Hal	is F, Cl, Br or I,

2002310904 14 Dec 2007

- 2 -

Het is a saturated, unsaturated or aromatic monocyclic or bicyclic heterocyclic radical having from 5 to 10 ring members, which may contain from 1 to 4 N and/or from 1 to 4 S and/or from 1 to 4 O atoms, and in which the heterocyclic radical may be
5 monosubstituted, disubstituted or trisubstituted by Hal, A, $-\text{C}(\text{R}^5)_2-\text{Ar}$, $-\text{C}(\text{R}^5)_2-\text{cycloalkyl}$, OR^5 , $\text{N}(\text{R}^5)_2$, NO_2 , CN , COOR^5 , $\text{CON}(\text{R}^5)_2$, NR^5COA , $\text{NR}^5\text{CON}(\text{R}^5)_2$, $\text{NR}^5\text{SO}_2\text{A}$, COR^5 , SO_2NR^5 or $\text{S}(\text{O})_m\text{A}$ and/or carbonyl oxygen,
10 Het¹ is a saturated, unsaturated or aromatic monocyclic, bicyclic or tricyclic heterocyclic radical having from 5 to 10 ring members which contains at least 1 N atom and in which the heterocyclic radical may be monosubstituted, disubstituted or trisubstituted by Hal, A, OR^5 , $\text{N}(\text{R}^5)_2$, NO_2 , CN and/or carbonyl oxygen,
15 n is 0, 1, 2, 3, 4, 5, 6, 7 or 8,
m is 1 or 2,
o is 0, 1, 2, 3 or 4,
and their physiologically acceptable salts and solvates.

The invention also relates to a compound of the general formula I



in which

A-B-D is $-\text{NR}^6-\text{CR}^2=\text{N}-$, $-\text{N}=\text{CR}^2-\text{NR}^6-$ or $-\text{N}=\text{CR}^7-\text{CR}^8=\text{N}-$,
R¹ is Het¹,
R² is H, A, cycloalkyl, $-(\text{CH}_2)_n-\text{N}(\text{R}^5)_2$, $-(\text{CH}_2)_n-\text{OR}^5$, $-(\text{CH}_2)_n-\text{Ar}$ or $-(\text{CH}_2)_n-\text{Het}$,
25 R³ is H, Hal, OH, OA or $\text{O}-(\text{CH}_2)_n-\text{Ar}$,
R⁴ is H, A or $-(\text{CH}_2)_n-\text{Ar}$,

2002310904 14 Dec 2007

- 2a -

R⁵ is H or A,
R⁶, R⁷ and R⁸ are each, independently of one another, H, A or -(CH₂)_n-Ar,
R⁷ and R⁸ together are alternatively alkylene having from 3 to 6 carbon atoms,
5 A is a linear or branched alkyl group having from 1 to 10 carbon atoms,
Ar is phenyl, naphthyl or biphenyl, each of which is unsubstituted or monosubstituted or polysubstituted by Hal, A, OR⁵, N(R⁵)₂, NO₂, CN, COOR⁵, CON(R⁵)₂, NR⁵COR⁵, NR⁵CON(R⁵)₂, NR⁵SO₂A, COR⁵, SO₂NR⁵ or S(O)_mA,
10 cycloalkyl is cycloalkyl having from 3 to 10 carbon atoms,
Hal is F, Cl, Br or I,
Het is a saturated, unsaturated or aromatic monocyclic or bicyclic 15 heterocyclic radical having from 5 to 10 ring members, which may contain from 1 to 4 N and/or from 1 to 4 S and/or from 1 to 4 O atoms, and in which the heterocyclic radical may be monosubstituted, disubstituted or trisubstituted by Hal, A, -[C(R⁵)₂]_o-Ar, -[C(R⁵)₂]_o-cycloalkyl, OR⁵, N(R⁵)₂, NO₂, CN, COOR⁵, CON(R⁵)₂, NR⁵COA, NR⁵CON(R⁵)₂, NR⁵SO₂A, COR⁵, SO₂NR⁵ or S(O)_mA and/or carbonyl oxygen,
20 Het¹ is a saturated, unsaturated or aromatic monocyclic, bicyclic or tricyclic heterocyclic radical having from 5 to 10 ring members which contains at least 1 N atom and in which the heterocyclic radical may be monosubstituted, disubstituted or trisubstituted by Hal, A, OR⁵, N(R⁵)₂, NO₂, CN and/or carbonyl oxygen,
25 n is 0, 1, 2, 3, 4, 5, 6, 7 or 8,
m is 1 or 2,
o is 0, 1, 2, 3 or 4,
30 or a physiologically acceptable salt or solvate thereof.

2002310904 14 Dec 2007

P:\WPDOCS\TXS\Specs\78287933 1spa.doc-13/12/2007

- 2b -

The invention involved finding novel compounds having valuable properties, in particular those which can be used for the preparation of medicaments.

It has been found that the compounds of the formula I and their physiologically acceptable salts and solvates are well tolerated and have valuable pharmacological properties since they act on the central nervous system.

5 The compounds are nicotinic acetylcholine receptor ligands and/or serotonergic ligands.

10 Of the well-characterised class of acetylcholine receptors, some members have been implicated in certain disorders of the central nervous system.

Known active ingredients which are able to interact with the acetylcholine

receptor class are, for example, pilocarpine, nicotine, lobeline and epibatidine.

5 These nicotinic acetylcholine receptors can be divided into two main classes, depending on the sites at which they occur.

10 The first class comprises the neuromuscular receptors. These are subdivided into ($\alpha_1\alpha_1\beta\delta$) and ($\alpha_1\alpha_1\beta\gamma\delta$) receptors. The second class comprises the neuronal nicotinic acetylcholine receptors, which are found in the ganglia. In these, a distinction is made between the ($\beta_2\beta_5$) receptors and the ($\alpha_2\alpha_9$) receptors, in this respect see also "Basic Neurochemistry", Ed. Siegel et al., Raven Press, New York, 1993.

15 The substances of the formula I are capable of interacting with each of these receptors. The substances of the formula I interact particularly well with the nicotinic α_7 receptor.

20 In-vitro evidence of the interaction with the nicotinic α_7 receptor can be obtained, for example, analogously to J.M. Ward et al., FEB 1990, 270, 45-48 or D.R.E. Macallan, FEB 1998, 226, 357-363.

25 Further in-vitro tests for nicotinic receptors are described in F.E. D'Amour et al., Manual for Laboratory Work in Mammalian Physiology, 3rd Ed., The University of Chicago Press (1965), W. Sihver et al., Neuroscience 1998, 85, 1121-1133 or B. Latli et al., J. Med. Chem. 1999, 42, 2227-2234.

25 Serotonergic ligands are ligands of the 5-HT₃ receptor and/or of the 5-HT₆ receptor.

30 5-HT₆ receptors form a sub-family of 5-HT receptors. The neurotransmitter 5-hydroxytryptamine (5-HT), also known as serotonin, is an important regulatory neurotransmitter in the brain whose actions are supported by a

family of receptors, which, as far as we know today, contain 13 G-protein-coupled receptors and an ion channel.

5 The greatest density of serotonin 5-HT₆ receptors in the brain is found in the tuberculum olfactorium, in the nucleus accumbens, in the striatum, in the gyrus dentatus and in the CA1-3 regions of the hippocampus. These regions are involved to a particularly great extent in psychiatric disorders, such as, for example, schizophrenia or depression. In addition, it is known from animal experiments that administration of 5-HT₆ antisense oligo-
10 nucleotides causes a behaviour syndrome which corresponds to that of dopamine agonists. Furthermore, hyperactivity of the dopaminergic neurotransmitter system is pathophysiologically safeguarded in schizophrenia (dopamine hypothesis of schizophrenia). However, dysfunctions of the dopamine system have also been found in various clinical forms of depression.
15 In addition, a large number of the established and also more recent therapeutic agents employed for the treatment of these psychiatric disorders in clinical practice bind to the 5-HT₆ receptor. Particular mention may be made here of atypical neuroleptics (for example clozapine) and the tricyclic antidepressants (for example amitriptyline).
20 In addition, it has been found in studies involving animal experiments that 5-HT₆ receptors in the brain control cholinergic neurotransmission. Cholinergics are employed in illnesses with memory disorders, such as, for example, Alzheimer's disease.
25 The efficacy of the compounds of the formula I as inhibitors of the 5-HT₃ receptor can be determined by the method of Richardson et al., Nature 1985, 316, 126 or by the method of Watling et al., European J. Pharmacol. 1988, 149, 397. Here, the compounds antagonise the action of serotonin at
30 5-HT₃ receptors, such as, for example, the serotonin-induced Bezold-Jarisch reflex (method, see J. Pharm. Pharmacol., 1980, 40, 301-302 and Nature 316, 126-131). In addition, these compounds displace the sub-

stance ^3H -GR65630, which is known as a selective 5-HT₃ ligand, from the homogenised tissue from the endorphinal cortex of rats (see *Europ. J. Pharmacol.*, 1989, 159, 157-164).

5 Illnesses which can be treated with the substances of the formula I thus include psychoses, schizophrenia, depression, anxiety states, dementia, in particular Alzheimer's disease and Lewy bodies dementia, neurodegenerative disorders, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, Tourette's syndrome, learning and memory restrictions, bulimia, anorexia nervosa or other eating disorders, compulsive behaviour, premenstrual syndrome, age-induced memory impairment, and amelioration of withdrawal symptoms in nicotine dependence. Owing to their neuroprotective action, compounds of the formula I are used in strokes and brain damage by toxic compounds. The compounds of the 10 formula I and their physiologically acceptable salts are therefore suitable as therapeutic active ingredients for disorders of the central nervous system.

15 The compounds are suitable for the treatment of disorders which are characterised by an excess of circulating serotonin or by serotonergic 20 hyperactivity. These include, in particular, psychoses, nausea and vomiting (occurring, for example, during chemotherapeutic or radiotherapeutic treatment of cancer diseases), irritable bowel syndrome, dementia or other cognitive disorders, migraine and addiction illnesses.

25 Compounds of the formula I and their salts and solvates are also suitable as intermediates for the preparation of other medicament active ingredients.


30 The invention relates to the compounds of the formula I and to their physiologically acceptable acid-addition salts. The invention also relates to the solvates, for example hydrates or alcoholates, of these compounds.

The term "solvates of the compounds of the formula I" is taken to mean adducts of inert solvent molecules onto the compounds of the formula I which form owing to their mutual attractive force. Solvates are, for example, monohydrates or dihydrates or addition compounds with alcohols, such as, for example, with methanol or ethanol.

Should radicals which have an asymmetrical carbon atom which can have different configurations be introduced via the radicals R¹ to R⁴, for example 1-azabicyclo[2.2.2]oct-3-yl for R¹, the compounds of the formula I may exist in various optically active forms or alternatively as racemates or racemate mixtures.

The invention relates to the compounds of the formula I and their salts and solvates according to Claim 1 and to a process for the preparation of compounds of the formula I in which

15 a) A-B-D is $-\text{NR}^6-\text{CR}^2=\text{N}-$ or $-\text{N}=\text{CR}^2-\text{NR}^6-$, and their salts and solvates, characterised in that a compound of the formula II




in which R^1 , R^3 and R^4 are as defined in Claim 1,
is reacted with a compound of the formula III
25
$$H_2N-CH_2-R^2 \quad III,$$

in which
 R^2 is as defined in Claim 1,
in the presence of an oxidant, and
if desired, the radical $R^1 = H$ is converted into another radical R^1 as
30 defined in Claim 1,
or


2002310904 14 Dec 2007

- 7 -

b) A-B-D is $-N=CR^7-CR^8=N-$, and their salts and solvates, characterised in that a compound of the formula IV



5 in which R^1 , R^3 and R^4 are as defined in Claim 1, is reacted with a compound of the formula V



in which

R^7 and R^8 are as defined in Claim 1,

in the presence of an oxidant, and

10 if desired, the radical $R^1 = H$ is converted into another radical R^1 as defined in Claim 1,

and/or


a base of the formula I obtained is converted into one of its salts by treatment with an acid.

15


The invention also relates to a process for the preparation of a compound of the formula I or a salt or solvate thereof according to claim 1 in which

a) A-B-D is $-NR^6-CR^2=N-$ or $-N=CR^2-NR^6-$, or a salt or solvate thereof, by reacting a compound of the formula II


- 7a -




in which R¹, R³ and R⁴ are as defined in Claims 1 to 3,
with a compound of the formula III



5 in which
R² is as defined in Claim 1,
in the presence of an oxidant,
or
10 b) A-B-D is -N=CR⁷-CR⁸=N-, or a salt or solvate thereof by reacting a
compound of the formula IV



in which R¹, R³ and R⁴ are as defined in Claims 1 to 3,
with a compound of the formula V



15 in which
R⁷ and R⁸ are as defined in Claim 1,
in the presence of an oxidant,
and/or

2002310904 14 Dec 2007

- 7b -

a base of the formula I obtained is converted into one of its salts by treatment with an acid.

The invention also relates to the compounds of the formula I according to Claim 5 1 and their physiologically acceptable salts and solvates as medicament active ingredients.

The invention likewise relates to the compounds of the formula I according to Claim 1 and their physiologically acceptable salts or solvates as ligands of the 10 nicotinic acetylcholine receptor.

The invention likewise relates to the compounds of the formula I according to Claim 1 and their physiologically acceptable salts or solvates as serotonergic ligands.

5 For all radicals which may occur more than once, such as, for example, A or Hal, their meanings are independent of one another.

A is linear or branched alkyl having from 1 to 10 carbon atoms and preferably has 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms. Alkyl having from 1 to 10 carbon atoms is preferably methyl, furthermore ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl or tert-butyl, furthermore also n-pentyl, 1-, 2- or 3-methylbutyl, n-hexyl, 1-, 2-, 3- or 4-methylpentyl, n-heptyl, 1-, 2-, 3- or 4-ethylpentyl, n-octyl, n-nonyl or n-decyl.
Alkyl is particularly preferably methyl.

15 Alkylene having from 3 to 6 carbon atoms is propylene, butylene, pentylene or hexylene. Alkylene is particularly preferably butylene.

20 Ar is phenyl, naphthyl or biphenyl, each of which is unsubstituted or monosubstituted or polysubstituted by Hal, A, OR⁵, N(R⁵)₂, NO₂, CN, COOR⁵, CON(R⁵)₂, NR⁵COR⁵, NR⁵CON(R⁵)₂, NR⁵SO₂A, COR⁵, SO₂NR⁵, SO₂NR⁵ or S(O)_mA, where A has one of the meanings indicated above, and R⁵ and m have one of the meanings indicated below.

25 Ar is preferably unsubstituted or substituted phenyl, naphthyl or biphenyl, specifically preferably phenyl, o-, m- or p-tolyl, o-, m- or p-ethylphenyl, o-, m- or p-propylphenyl, o-, m- or p-isopropylphenyl, o-, m- or p-tert-butylphenyl, o-, m- or p-trifluoromethylphenyl, o-, m- or p-aminophenyl, o-, m- or p-hydroxyphenyl, o-, m- or p-nitrophenyl, o-, m- or p-(trifluoromethoxy)phenyl, o-, m- or p-cyanophenyl, o-, m- or p-methoxyphenyl, o-, m- or p-ethoxyphenyl, o-, m- or p-fluorophenyl, o-, m- or p-bromophenyl, o-, m- or p-chlorophenyl, o-, m- or p-(difluoromethoxy)phenyl, o-, m- or p-(fluoro-

methoxy)phenyl, furthermore preferably 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-difluorophenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dichlorophenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dibromophenyl, 2-chloro-3-methyl-, 2-chloro-4-methyl-, 2-chloro-5-methyl-, 2-chloro-6-methyl-, 2-methyl-3-chloro-, 2-methyl-4-chloro-, 2-methyl-5-chloro-, 2-methyl-6-chloro-, 3-chloro-4-methyl-, 3-chloro-5-methyl- or 3-methyl-4-chlorophenyl, 2-bromo-3-methyl-, 2-bromo-4-methyl-, 2-bromo-5-methyl-, 2-bromo-6-methyl-, 2-methyl-3-bromo-, 2-methyl-4-bromo-, 2-methyl-5-bromo-, 2-methyl-6-bromo-, 3-bromo-4-methyl-, 3-bromo-5-methyl- or 3-methyl-4-bromophenyl, 2,4- or 2,5-dinitrophenyl, 2,5- or 3,4-dimethoxyphenyl, 3-nitro-4-chlorophenyl, 2,3,4-, 2,3,5-, 2,3,6-, 2,4,6- or 3,4,5-trichlorophenyl, 2,4,6-tri-tert-butylphenyl, furthermore preferably 2-nitro-4-(trifluoromethyl)phenyl, 3,5-di(trifluoromethyl)phenyl, 2,5-dimethylphenyl, 2-hydroxy-3,5-dichlorophenyl, 2-fluoro-5- or 4-fluoro-3-(trifluoromethyl)phenyl, 4-chloro-2- or 4-chloro-3-(trifluoromethyl)-, 2-chloro-4- or 2-chloro-5-(trifluoromethyl)phenyl, 4-bromo-2- or 4-bromo-3-(trifluoromethyl)phenyl, p-iodophenyl, 2-nitro-4-methoxyphenyl, 2,5-dimethoxy-4-nitrophenyl, 2-methyl-5-nitrophenyl, 2,4-dimethyl-3-nitrophenyl, 4-fluoro-3-chlorophenyl, 4-fluoro-3,5-dimethylphenyl, 2-fluoro-4-bromophenyl, 2,5-difluoro-4-bromophenyl, 2,4-dichloro-5-methylphenyl, 3-bromo-6-methoxyphenyl, 3-chloro-6-methoxyphenyl, 2-methoxy-5-methylphenyl or 2,4,6-triisopropylphenyl.

Ar is particularly preferably, i.e. $-(CH_2)_n-Ar$ where $n = 0$, phenyl or o -methoxyphenyl. $-(CH_2)_n-Ar$ where $n = 0$ is very particularly preferably phenyl.

$-(CH_2)_n-Ar$ is arylalkyl if Ar has one of the meanings indicated above and n is 1, 2, 3, 4, 5, 6, 7 or 8. $-(CH_2)_n-Ar$ where $n \neq 0$ is preferably benzyl, phenylethyl, phenylpropyl, phenylbutyl, phenylpentyl, phenylhexyl, phenylheptyl, naphthylmethyl, naphthylethyl, naphthylpropyl or naphthylbutyl. $-(CH_2)_n-Ar$ is particularly preferably benzyl or phenylethyl.

Cycloalkyl having from 3 to 10 carbon atoms is preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or 2,6,6-trimethylbicyclo[3.1.1]heptyl.

5 Cycloalkyl is likewise a monocyclic or bicyclic terpene, preferably p-menthane, menthol, pinane, bornane or camphor, including all known stereoisomeric forms, or adamantyl. For camphor, this is either L-camphor or D-camphor.

10 Cycloalkyl is particularly preferably 2,6,6-trimethylbicyclo[3.1.1]heptyl.

15 Hal is fluorine, chlorine, bromine or iodine, particularly preferably fluorine, chlorine or bromine.

20 Het is a saturated, unsaturated or aromatic monocyclic or bicyclic heterocyclic radical having from 5 to 10 ring members, which may contain from 1 to 4 N and/or from 1 to 4 S and/or from 1 to 4 O atoms and in which the heterocyclic radical may be monosubstituted, disubstituted or trisubstituted by Hal, A, $-\text{C}(\text{R}^5)_2\text{o}-\text{Ar}$, $-\text{C}(\text{R}^5)_2\text{o}-\text{cycloalkyl}$, OR^5 , $\text{N}(\text{R}^5)_2$, NO_2 , CN , COOR^5 , $\text{CON}(\text{R}^5)_2$, NR^5COA , $\text{NR}^5\text{CON}(\text{R}^5)_2$, $\text{NR}^5\text{SO}_2\text{A}$, COR^5 , SO_2NR^5 or $\text{S}(\text{O})_m\text{A}$ and/or carbonyl oxygen, where A, Hal, Ar and cycloalkyl have one of the meanings indicated above, and R^5 , o and m are as defined below.

25 Het is preferably substituted or unsubstituted 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, furthermore preferably 1,2,3-triazol-1-, -4- or -5-yl, 1,2,4-triazol-1-, -4- or -5-yl, 1- or 5-tetrazolyl, 1,2,3-oxadiazol-4- or -5-yl, 1,2,4-oxadiazol-3- or -5-yl, 1,3,4-thiadiazol-2- or -5-yl, 1,2,4-thiadiazol-3- or -5-yl, 1,2,3-thiadiazol-4- or -5-yl, 2-, 3-, 4-, 5- or 6-2H-thiopyranyl, 2-, 3- or 4-4H-thiopyranyl, 3- or 4-pyridazinyl, pyrazinyl, 2-, 3-, 4-, 5-, 6- or 7-benzofuryl, 2-, 3-, 4-, 5-, 6- or 7-benzothienyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-1H-indolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or 7-

benzopyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 3-, 4-, 5-, 6- or 7-benzisoxazolyl, benzo-1,3-dioxol-5-yl, -6-yl, -7-yl or -4-yl, 2-, 4-, 5-, 6- or 7-benzothiazolyl, 4- or 5-benzothiadiazolyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 4-, 5-, 6- or 7-benz-2,1,3-oxadiazolyl, 1-, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolinyl, 5 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolinyl, 1-, 2-, 3-, 4- or 9-carbazolyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-acridinyl, 3-, 4-, 5-, 6-, 7- or 8-cinnolinyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl. The heterocyclic radicals may also be partially or fully hydrogenated. Het may thus also be 2,3-dihydro-2-, -3-, -4- or -5-furyl, 2,5-dihydro-2-, -3-, -4- or -5-furyl, tetrahydro-2- or -3-furyl, 1,3-dioxolan-4-yl, 10 tetrahydro-2- or -3-thienyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 2,5-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 1-, 2- or 3-pyrrolidinyl, tetrahydro-1-, -2- or -3-pyrrolyl, tetrahydro-1-, -2- or -4-imidazolyl, 2,3-dihydro-1-, -2-, -3-, -4-, -5-, -6- or -7-1H-indolyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrazolyl, tetrahydro-1-, -3- or -4-pyrazolyl, 1,4-dihydro-1-, -2-, -3- or -4-pyridyl, 15 1,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5- or -6-pyridyl, 1,2,3,6-tetrahydro-1-, -2-, -3-, -4-, -5- or -6-pyridyl, 1-, 2-, 3- or 4-azepanyl, 2-, 3- or 4-morpholinyl, tetrahydro-2-, -3- or -4-pyranyl, 1,4-dioxanyl, 1,3-dioxan-2-, -4- or -5-yl, hexahydro-1-, -3- or -4-pyridazinyl, hexahydro-1-, -2-, -4- or -5-pyrimidinyl, 1-, 2- or 3-piperazinyl, 1,2,3,4- 20 tetrahydro-1-, -2-, -3-, -4-, -5-, -6-, -7- or -8-quinolinyl, 1,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5-, -6-, -7- or -8-isoquinolinyl.

Het is particularly preferably imidazol-1-yl, 6-methoxy-1H-indol-3-yl, pyridin-3-yl or 4-methylpiperazin-1-yl.

25 -(CH₂)_n-Het is particularly preferably pyridin-3-yl, 6-methoxy-1H-indol-3-ylmethyl, (4-methyl)piperidin-1-ylethyl or imidazol-1-ylethyl.

Het¹ is a saturated, unsaturated or aromatic monocyclic, bicyclic or tricyclic heterocyclic radical having from 5 to 10 ring members which contains at least 1 N atom and in which the heterocyclic radical may be monosubstituted

ted, disubstituted or trisubstituted by Hal, A, OR⁵, N(R⁵)₂, NO₂, CN and/or carbonyl oxygen, where A is as defined above, and R⁵ is as defined below.

Het¹ is preferably substituted or unsubstituted 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 3-, 4- or 5-pyrazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, furthermore preferably 3- or 4-pyridazinyl, pyrazinyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-1H-indolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzopyrazolyl, 1-, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolinyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinoliny, 3-, 4-, 5-, 6-, 7- or 8-cinnolinyl, 1-, 4-, 5-, 6-, 7- or 8-phthalazinyl, 2-, 3-, 5-, 6-, 7- or 8-quinoxaliny, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl. The heterocyclic radicals may also be partially or fully hydrogenated. Het¹ may thus also be 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 2,5-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 1-, 2- or 3-pyrrolidinyl, tetrahydro-1-, -2- or -3-pyrrolyl, tetrahydro-1-, -2- or -4-imidazolyl, 2,3-dihydro-1-, -2-, -3-, -4-, -5-, -6- or -7-1H-indolyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrazolyl, tetrahydro-1-, -3- or -4-pyrazolyl, 1,5-dihydroimidazol-4-on-2- or -5-yl, 1,4-dihydro-1-, -2-, -3- or -4-pyridyl, 1,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5- or -6-pyridyl, 1,2,3,6-tetrahydro-1-, -2-, -3-, -4-, -5- or -6-pyridyl, 1-, 2-, 3- or 4-piperidinyl, 1-, 2-, 3- or 4-azepanyl, tetrahydro-2-, -3- or -4-pyranyl, hexahydro-1-, -3- or -4-pyridazinyl, hexahydro-1-, -2-, -4- or -5-pyrimidinyl, 1-, 2- or 3-piperazinyl, 1,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5-, -6-, -7- or -8-quinoliny, 1,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5-, -6-, -7- or -8-isoquinoliny or 1-azabicyclo[2.2.2]oct-3-yl. A synonym for 1-azabicyclo[2.2.2]oct-3-yl is quinuclidin-3-yl.

The said heterocyclic rings may also be monosubstituted or disubstituted by =O or NHR⁵.

Het¹ is particularly preferably 1-azabicyclo[2.2.2]oct-3-yl, piperidin-3-yl, piperidin-4-yl or 1-methylpiperidin-4-yl. Het¹ is very particularly preferably 1-azabicyclo[2.2.2]oct-3-yl.

A-B-D is $-\text{NR}^6-\text{CR}^2=\text{N}-$, $-\text{N}=\text{CR}^2-\text{NR}^6-$ or $-\text{N}=\text{CR}^7-\text{CR}^8=\text{N}-$, where R^2 , R^6 , R^7 and R^8 have one of the meanings mentioned below. The compounds in which A-B-D is $-\text{NH}-\text{CR}^2=\text{N}-$ or $-\text{N}=\text{CR}^2-\text{NH}-$ are generally mixtures of the two isomers, which are present in approximately equal proportions. The 5 isomers are also referred to as tautomers, i.e. they are constitutional isomers which can be converted into one another by overcoming a relatively low energy threshold.

R^1 is hydrogen or Het^1 , where Het^1 is as defined above.
10 R^1 is preferably hydrogen or 1-azabicyclo[2.2.2]oct-3-yl, particularly preferably 1-azabicyclo[2.2.2]oct-3-yl.

R^2 is H, A, cycloalkyl, $-(\text{CH}_2)_n-\text{N}(\text{R}^5)_2$, $-(\text{CH}_2)_n-\text{OR}^5$, $-(\text{CH}_2)_n-\text{Ar}$ or $-(\text{CH}_2)_n-\text{Het}$, where R^5 is as defined below, and n may be 0, 1, 2, 3, 4, 5, 6, 15 7 or 8. A, cycloalkyl, Ar and Het have the preferred and particularly preferred meanings indicated above.

n is preferably 1 or 2.
20 R^2 is preferably A, phenyl, pyridin-3-yl, 6-methoxy-1H-indol-3-ylmethyl, 2-dimethylaminoethyl, (4-methyl)piperidin-1-ylethyl or imidazol-1-ylethyl.

R^3 is H, Hal, OH, OA or $\text{O}-(\text{CH}_2)_n-\text{Ar}$, where Hal, A, Ar and n are as defined above.
25 R^3 is preferably hydrogen.

R^4 is H, A or $\text{O}-(\text{CH}_2)_n-\text{Ar}$, where A, Ar and n are as defined above.
20 R^4 is preferably hydrogen.

R^5 is H or A, where A is as defined above.
30 $-(\text{CH}_2)_n-\text{OR}^5$ is particularly preferably methoxymethyl.
 $-(\text{CH}_2)_n-\text{N}(\text{R}^5)_2$ is particularly preferably 2-dimethylaminoethyl.

R^6 , R^7 and R^8 are each, independently of one another, H, A or $-(\text{CH}_2)_n-\text{Ar}$.

R^6 is particularly preferably hydrogen.

R^7 is particularly preferably A.

R^8 is particularly preferably hydrogen.

5 R^7 and R^8 together may also be alkylene having from 3 to 6 carbon atoms.
 R^7 and R^8 together are particularly preferably butylene.

m is 1 or 2, where m is preferably 2.

o is 0, 1, 2, 3 or 4. o is preferably 0 or 1.

10

The invention accordingly relates, in particular, to the compounds of the formula I in which at least one of the said radicals has one of the preferred meanings indicated above. Some preferred groups of compounds may be expressed by the following sub-formulae Ia to Ij, which conform to the formula I and in which the radicals not designated in greater detail have the meaning indicated for the formula I, but in which

in Ia R^4 is hydrogen;

20 in Ib R^3 is hydrogen;

in Ic R^3 is hydrogen, and
 R^4 is hydrogen;

25 in Id R^1 is Het¹;

in Ie R^3 is hydrogen,
 R^4 is hydrogen, and
 R^1 is Het¹;

30 in If A-B-D is -NR⁵-CR²=N- or -N=CR²-NR⁵-, and
 R^6 is hydrogen;

in Ig A-B-D is $-NR^6-CR^2=N-$ or $-N=CR^2-NR^6-$,
R¹ is Het¹,
R² is A, $-(CH_2)_n-N(R^5)_2$, $-(CH_2)_n-Ar$ or $-(CH_2)_n-Het$,
5 R³ is hydrogen,
R⁴ is hydrogen, and
R⁶ is hydrogen;

in Ih A-B-D is $-N=CR^7-CR^8=N-$;
10 in ii A-B-D is $-N=CR^7-CR^8=N-$,
R¹ is Het¹,
R³ is hydrogen,
R⁴ is hydrogen,
15 R⁷ is hydrogen or A, and
R⁸ is hydrogen;

in Ij A-B-D is $-N=CR^7-CR^8=N-$,
R¹ is Het¹,
20 R³ is hydrogen,
R⁴ is hydrogen, and
R⁷ and R⁸ together are alkylene having from 3 to 6 carbon atoms.

25 The invention relates, in particular, to the compounds according to Claim 7
and their salts and solvates.

30 The compounds of the formula I and also the starting materials for their
preparation are, in addition, prepared by methods known per se, as de-
scribed in the literature (for example in the standard works, such as Houben-
Weyl, Methoden der Organischen Chemie [Methods of Organic Chemistry],
Georg Thieme Verlag, Stuttgart; Organic Reactions, John Wiley & Sons,
Inc., New York), to be precise under reaction conditions as are known and

suitable for the said reactions. Use can also be made here of variants which are known per se, but are not mentioned here in greater detail.

5 The starting materials for the claimed process can also be formed in situ by not isolating them from the reaction mixture, but instead immediately converting them further into the compounds of the formula I. On the other hand, it is possible to carry out the reaction in steps.

10 The compounds of the formula I in which A-B-D is $-NR^6-CR^2=N-$ or $-N=CR^2-NR^6-$ can preferably be obtained by reacting compounds of the formula II, in which R^1 , R^3 and R^4 are as defined in Claim 1, with compounds of the formula III, in which R^2 is as defined in Claim 1.

15 Compounds of the formula II can be prepared, for example, by reaction of 5-nitro-1H-indole with an oxo-substituted heterocyclic radical Het¹ in the presence of a base followed by hydrogenation. An example of an oxo-substituted heterocyclic radical Het¹ is 3-quinuclidinone. The base used is advantageously sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium carbonate, potassium carbonate or ammonia. The 20 solvent selected is preferably water, lower alcohols, such as methanol or ethanol, ethers, such as tetrahydrofuran (THF) or dioxane, sulfones, such as tetramethylene sulfone, or mixtures thereof, particularly water-containing mixtures.

25 The hydrogenation is carried out under standard conditions, preferably in the presence of Pd/C.

30 The amines of the formula III are generally known or are commercially available; the compounds of the formula III which are not known can easily be prepared analogously to the known compounds.

The reaction of compounds of the formula II with amines of the formula III is carried out in the presence of an oxidant.

Suitable oxidants are manganese oxide (MnO_2), hydrogen peroxide (H_2O_2), ozone (O_3), potassium permanganate, chromium oxide, sodium chromate or potassium chromate.

Examples of suitable inert solvents are hydrocarbons, such as hexane, 5 petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons, such as trichloroethylene, 1,2-dichloroethane, carbon tetrachloride, chloroform or dichloromethane; ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers, such as ethylene glycol monomethyl or monoethyl ether, ethylene glycol dimethyl ether (diglyme); 10 ketones, such as acetone or butanone; amides, such as acetamide, N-methylpyrrolidone (NMP), dimethylacetamide or dimethylformamide (DMF); nitriles, such as acetonitrile; sulfoxides, such as dimethyl sulfoxide (DMSO); carbon disulfide; carboxylic acids, such as formic acid or acetic acid; nitro compounds, such as nitromethane or nitrobenzene; esters, such 15 as ethyl acetate, or mixtures of the said solvents.

Depending on the conditions used, the reaction temperature is between about -10° and 150°, normally between 0° and 130°, preferably between 0° and 50°, particularly preferably room temperature.

Depending on the conditions used, the reaction time is between a few 20 minutes and several days.

The compounds of the formula I in which A-B-D is $-N=CR^7-CR^8=N-$ can 25 preferably be obtained by reacting compounds of the formula IV, in which R^1 , R^3 and R^4 are as defined in Claim 1, with compounds of the formula V, in which R^7 and R^8 are as defined in Claim 1.

Compounds of the formula IV and their preparation are disclosed in EP 450 345 (EP 450 345 B1: column 3, line 8, to column 4, line 38). EP 450 345 is incorporated herein by way of reference.

Diamines of the formula V are generally known or commercially available; the compounds of the formula V which are not known can easily be prepared analogously to the known compounds.

5 The reaction of compounds of the formula IV with diamines of the formula V is carried out in the presence of an oxidant, under reaction conditions as described above.
 Suitable oxidants are likewise manganese dioxide (MnO_2), hydrogen peroxide (H_2O_2), ozone (O_3), potassium permanganate, chromium oxide,
10 sodium chromate or potassium chromate.

A base of the formula I obtained can be converted into the associated acid-addition salt using an acid. Suitable acids for this reaction are those which give physiologically acceptable salts. Thus, it is possible to use inorganic acids, for example sulfuric acid, hydrohalic acids, such as hydrochloric acid or hydrobromic acid, phosphoric acids, such as orthophosphoric acid, nitric acid, sulfamic acid, furthermore organic acids, specifically aliphatic, alicyclic, araliphatic, aromatic or heterocyclic monobasic or polybasic carboxylic, sulfonic or sulfuric acids, such as formic acid, acetic acid,
15 propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, lactic acid, tartaric acid, malic acid, benzoic acid, salicylic acid, 2-phenylpropionic acid, citric acid, gluconic acid, ascorbic acid, nicotinic acid, isonicotinic acid, methane- or ethane-sulfonic acid, ethanedisulfonic acid, 2-hydroxyethanesulfonic acid,
20 benzenesulfonic acid, p-toluenesulfonic acid, naphthalenemono- and -disulfonic acids and laurylsulfuric acid.

The free bases of the formula I can, if desired, be liberated from their salts by treatment with strong bases, such as sodium hydroxide, potassium hydroxide, sodium carbonate or potassium carbonate, so long as no further acidic groups are present in the molecule.
30

The invention furthermore relates to the medicament active ingredients according to the invention as nicotinic acetylcholine receptor ligands and/or serotonergic ligands for the prophylaxis or treatment of schizophrenia, depression, anxiety states, dementia, Alzheimer's disease, Lewy bodies 5 dementia, neurodegenerative disorders, Parkinson's disease, Huntington's disease, Tourette's syndrome, learning and memory restrictions, age-induced memory impairment, amelioration of withdrawal symptoms in nicotine dependence, strokes or brain damage by toxic compounds.

10 The invention furthermore relates to pharmaceutical preparations comprising at least one compound of the formula I and/or one of its physiologically acceptable salts or solvates. The compounds of the formula I here can be converted into a suitable dosage form together with at least one solid, liquid and/or semi-liquid excipient or adjuvant and if desired in combination with one or more further active ingredients.

15 These preparations can be used as medicaments in human or veterinary medicine. Suitable excipients are organic or inorganic substances which are suitable for enteral (for example oral), parenteral or topical administration 20 and which do not react with the novel compounds, for example water, vegetable oils, benzyl alcohols, alkylene glycols, polyethylene glycols, glycerol triacetate, gelatine, carbohydrates, such as lactose or starch, magnesium stearate, talc and Vaseline. Suitable for oral administration are, in particular, tablets, pills, coated tablets, capsules, powders, granules, 25 syrups, juices or drops, suitable for rectal administration are suppositories, suitable for parenteral administration are solutions, preferably oil-based or aqueous solutions, furthermore suspensions, emulsions or implants, and suitable for topical application are ointments, creams or powders. The novel compounds may also be lyophilised and the resultant lyophilisates 30 used, for example, for the preparation of injection preparations. The preparations indicated may be sterilised and/or comprise adjuvants, such as lubricants, preservatives, stabilisers and/or wetting agents, emulsifiers,

2002310904 14 Dec 2007

- 20 -

salts for modifying the osmotic pressure, buffer substances, colorants, flavours and/or a plurality of further active ingredients, for example one or more vitamins.

5 The substances according to the invention are generally administered analogously to known, commercially available preparations (for example Tae-rin), preferably in doses of between about 5 mg and 100 mg, in particular between 10 and 40 mg per dosage unit. The daily dose is preferably between about 0.5 and 1 mg/kg of body weight.

10

The specific dose for each individual patient depends on a very wide variety of factors, for example on the efficacy of the specific compound employed, on the age, body weight, general state of health, sex, on the diet, on the time and method of administration, on the excretion rate, medicament combination and

15 severity of the particular disorder to which the therapy applies.

Oral administration is preferred.

The above-mentioned compounds of the formula I are used for the preparation of medicaments, in particular medicaments which are employed for the

20 treatment of disorders based on dysfunction of nicotinic acetylcholine receptors.

The invention likewise relates to the use of compounds of the formula I according to Claim 1 and/or their physiologically acceptable salts or solvates for

25 the preparation of a medicament, in particular for the preparation of a medicament for the treatment of disorders in which the binding to nicotinic acetylcholine receptors results in an improvement in the clinical picture.

- 21 -

The invention also relates to a method of treating disorders in which excitation of the nicotinic acetylcholine receptors results in an improvement in the clinical picture comprising administering to a subject in need thereof at least one compound of the formula I as defined in claim 1 and/or a physiologically acceptable salt or solvate thereof.

The invention furthermore relates to the use of compounds of the formula I according to Claim 1 and/or of their physiologically acceptable salts and solvates for the preparation of a medicament for the prophylaxis or treatment of psychoses, schizophrenia, depression, anxiety states, dementia, in particular Alzheimer's disease and Lewy bodies dementia, neurodegenerative disorders, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, Tourette's syndrome, learning and memory restrictions, bulimia, anorexia nervosa or other eating disorders, compulsive behaviour, premenstrual syndrome, age-induced memory impairment, amelioration of withdrawal symptoms in nicotine dependence, strokes or brain damage by toxic compounds.

The invention also relates to a method of preventing or treating psychoses, schizophrenia, depression, anxiety states, dementia, Alzheimer's disease, Lewy bodies dementia, neurodegenerative disorders, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, Tourette's syndrome, learning or memory restrictions, bulimia, anorexia nervosa or other eating disorders, compulsive behaviour, premenstrual syndrome, age-induced memory impairment, amelioration of withdrawal symptoms in nicotine dependence, stroke or brain damage by toxic compounds comprising administering to a subject in need thereof at least one compound of the formula I as defined in claim 1 and/or a physiologically acceptable salt or solvate thereof.

30

- 21a -

The invention furthermore relates to the use of compounds of the formula I according to Claim 1 and/or of their physiologically acceptable salts and solvates for the preparation of a medicament for the treatment of disorders that are characterised by an excess of circulating serotonin or by serotonergic hyperactivity, in particular of nausea or vomiting.

The invention also relates to a method of treating disorders which are characterised by an excess of circulating serotonin or by serotonergic hyperactivity comprising administering to a subject in need thereof at least one compound of the formula I as defined in claim 1 and/or a physiologically acceptable salt or solvate thereof.

Even without further details, it is assumed that a person skilled in the art will be able to use the above description in the broadest scope. The preferred embodiments should therefore merely be regarded as descriptive disclosure which is absolutely not limiting in any way.

Above and below, all temperatures are given in °C. In the following examples, "conventional work-up" means that, if necessary, the solvent is removed, water is added if necessary, the pH is, if necessary, adjusted to between 2 and 10, depending on the constitution of the end product, the mixture is extracted with ethyl acetate or dichloromethane, the phases are separated, the organic phase is dried over sodium sulfate, filtered and evaporated, and the product is purified by chromatography on silica gel and/or by crystallisation. The purified compounds are, if desired, freeze-dried.

Mass spectrometry (MS): ESI (electrospray ionisation) (M+H)⁺

Particular embodiments of the invention will now be described by way of the following non-limiting examples.

Example 1:

1) 44.8 mmol of 1-azabicyclo[2.2.2]octan-3-one hydrochloride (3-quinuclidinone hydrochloride) and 112 mmol of potassium hydroxide are added to a solution of 22.4 mmol of 5-nitro-1H-indole in 100 ml of water/methanol (1/1), and the mixture is stirred at the boiling point for 48 hours. The crystals which deposit on cooling of the reaction solution are filtered off, washed and dried, giving 3-(5-nitro-1H-indol-3-yl)-1-azabicyclo[2.2.2]oct-2-ene.

5

10 2) 0.2 g of Pd/C (10%) is added to a suspension of 7.4 mmol of 3-(5-nitro-1H-indol-3-yl)-1-azabicyclo[2.2.2]oct-2-ene in 50 ml of methanol, and the mixture is stirred at room temperature for 12 hours in a hydrogen atmosphere at atmospheric pressure. The mixture is filtered, and the filter residue is subjected to conventional work-up, giving 3-(1-azabicyclo[2.2.2]oct-3-yl)-1H-indol-5-ylamine.

15

Reaction of the free base with 1N HCl solution in methanol gives 3-(1-azabicyclo[2.2.2]oct-3-yl)-1H-indol-5-ylamine dihydrochloride.

20 3) 2 mmol of ethylamine and 10 mmol of MnO₂ are added to a solution of 1 mmol of 3-(1-azabicyclo[2.2.2]oct-3-yl)-1H-indol-5-ylamine in 20 ml of dimethylformamide (DMF), and the mixture is stirred at room temperature for 12 hours. The suspension is filtered through Celite and washed with DMF. After the solvent has been distilled, the mixture is subjected to conventional work-up, giving 8-(1-azabicyclo[2.2.2]oct-3-yl)-2-methyl-3,6-dihydroimidazo[4,5-e]indole; ESI 281.

25

For all the compounds indicated, mixtures of the compounds in the ratio of about 1:1 are formed, as described above. If the tautomers have been isolated, the two isomers are then listed separately, otherwise only the

30 name of one isomer is given.

For Example 1 and all further examples, the following therefore applies:

8-(1-azabicyclo[2.2.2]oct-3-yl)-2-methyl-3,6-dihydroimidazo[4,5-e]indole is a 1:1 mixture of the tautomeric forms 8-(1-azabicyclo[2.2.2]oct-3-yl)-2-methyl-3,6-dihydroimidazo[4,5-e]indole and 8-(1-azabicyclo[2.2.2]oct-3-yl)-2-methyl-1,6-dihydroimidazo[4,5-e]indole. The same applies to the salts indicated.

Reaction of the free base with 2N HCl solution in methanol gives 8-(1-aza-bicyclo[2.2.2]oct-3-yl)-2-methyl-3,6-dihydroimidazo[4,5-e]indole hydrochloride.

10

Example 2:

Analogously to Example 1, reaction of 3-(1-azabicyclo[2.2.2]oct-3-yl)-1H-indol-5-ylamine with

15 N^1,N^1 -dimethylpropane-1,3-diamine gives
{2-[8-(1-azabicyclo[2.2.2]oct-3-yl)-3,6-dihydroimidazo[4,5-e]indol-2-yl]-ethyl}dimethylamine, ESI 338;
salt precipitation with 2N HCl solution gives
{2-[8-(1-azabicyclo[2.2.2]oct-3-yl)-3,6-dihydroimidazo[4,5-e]indol-2-yl]ethyl}-
20 dimethylamine dihydrochloride,

3-imidazol-1-ylpropylamine gives
8-(1-azabicyclo[2.2.2]oct-3-yl)-2-(2-imidazol-1-yl-ethyl)-3,6-dihydroimidazo[4,5-e]indole, ESI 361;
25 salt precipitation with 2N HCl solution gives
8-(1-azabicyclo[2.2.2]oct-3-yl)-2-(2-imidazol-1-yl-ethyl)-3,6-dihydroimidazo[4,5-e]indole dihydrochloride,

30 3-(4-methylpiperazin-1-yl)propylamine gives
8-(1-azabicyclo[2.2.2]oct-3-yl)-2-[2-(4-methylpiperazin-1-yl)ethyl]-3,6-dihydroimidazo[4,5-e]indole, ESI 394;
salt precipitation with 2N HCl solution gives

8-(1-azabicyclo[2.2.2]oct-3-yl)-2-[2-(4-methylpiperazin-1-yl)ethyl]-3,6-dihydroimidazo[4,5-e]indole dihydrochloride,

2-(6-methoxy-1H-indol-3-yl)ethylamine gives

5 8-(1-azabicyclo[2.2.2]oct-3-yl)-2-(6-methoxy-1H-indol-3-ylmethyl)-3,6-dihydroimidazo[4,5-e]indole, ESI 427;
salt precipitation with 2N HCl solution gives
8-(1-azabicyclo[2.2.2]oct-3-yl)-2-(6-methoxy-1H-indol-3-ylmethyl)-3,6-dihydroimidazo[4,5-e]indole hydrochloride,

10

benzylamine gives

8-(1-azabicyclo[2.2.2]oct-3-yl)-2-phenyl-3,6-dihydroimidazo[4,5-e]indole,
ESI 343;
salt precipitation with 2N HCl solution gives
15 8-(1-azabicyclo[2.2.2]oct-3-yl)-2-phenyl-3,6-dihydroimidazo[4,5-e]indole
hydrochloride,

C-pyridin-3-ylmethylamine gives

20 8-(1-azabicyclo[2.2.2]oct-3-yl)-2-pyridin-3-yl-3,6-dihydroimidazo[4,5-e]-indole, ESI 344;
salt precipitation with 2N HCl solution gives
8-(1-azabicyclo[2.2.2]oct-3-yl)-2-pyridin-3-yl-3,6-dihydroimidazo[4,5-e]indole dihydrochloride.

25

Example 3:

0.2 mmol of ethane-1,2-diamine and 1 mmol of MnO₂ are added to a solution of 0.1 mmol of 3-(1-azabicyclo[2.2.2]oct-3-yl)-1H-indol-5-ol (prepared analogously to Example 1.1 to 1.2 by reaction of 5-hydroxy-1H-indole with 3-quinuclidinone followed by hydrogenation) in 2 ml of DMF, and the mixture is stirred at room temperature for 18 hours. The suspension is filtered through Celite and subjected to conventional work-up, giving 9-(1-aza-bicyclo[2.2.2]oct-3-yl)-7H-pyrrolo[3,2-f]quinoxaline; ESI 279.

Reaction of the free base with 2N HCl solution in methanol gives 9-(1-aza-bicyclo[2.2.2]oct-3-yl)-7H-pyrrolo[3,2-f]quinoxaline hydrochloride.

Example 4:

5 Analogously to Example 3, reaction of 9-(1-azabicyclo[2.2.2]oct-3-yl)-7H-pyrrolo[3,2-f]quinoxaline with propane-1,2-diamine gives
9-(1-azabicyclo[2.2.2]oct-3-yl)-3-methyl-7H-pyrrolo[3,2-f]quinoxaline; ESI 10 293;
salt precipitation with 2N HCl solution gives
9-(1-azabicyclo[2.2.2]oct-3-yl)-3-methyl-7H-pyrrolo[3,2-f]quinoxaline hydrochloride,
15 cyclohexane-1,2-diamine gives
1-(1-azabicyclo[2.2.2]oct-3-yl)-7,8,9,10-tetrahydro-3H-pyrrolo[3,2-a]-phenazine; ESI 333;
salt precipitation with 2N HCl solution gives
1-(1-azabicyclo[2.2.2]oct-3-yl)-7,8,9,10-tetrahydro-3H-pyrrolo[3,2-a]-phenazine hydrochloride.
20

The examples below relate to pharmaceutical preparations:

Example A: Injection vials

25 A solution of 100 g of an active ingredient of the formula I and 5 g of disodium hydrogenphosphate in 3 l of bidistilled water is adjusted to pH 6.5 using 2N hydrochloric acid, sterile filtered, transferred into injection vials, lyophilised and sealed under sterile conditions. Each injection vial contains 5 mg of active ingredient.

30 Example B: Suppositories

A mixture of 20 g of an active ingredient of the formula I is melted with

100 g of soya lecithin and 1400 g of cocoa butter, poured into moulds and allowed to cool. Each suppository contains 20 mg of active ingredient.

Example C: Solution

5 A solution is prepared from 1 g of an active ingredient of the formula I, 9.38 g of $\text{NaH}_2\text{PO}_4 \times 2 \text{ H}_2\text{O}$, 28.48 g of $\text{Na}_2\text{HPO}_4 \times 12 \text{ H}_2\text{O}$ and 0.1 g of benzalkonium chloride in 940 ml of bidistilled water. The pH is adjusted to 6.8, and the solution is made up to 1 l and sterilised by irradiation. This solution can be used in the form of eye drops.

10

Example D: Ointment

500 mg of an active ingredient of the formula I are mixed with 99.5 g of Vaseline under aseptic conditions.

15

Example E: Tablets

A mixture of 1 kg of active ingredient of the formula I, 4 kg of lactose, 1.2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is pressed to give tablets in a conventional manner in such a way that each tablet contains 10 mg of active ingredient.

20

Example F: Coated tablets

Tablets are pressed analogously to Example E and subsequently coated in a conventional manner with a coating of sucrose, potato starch, talc, tragacanth and dye.

25

Example G: Capsules

2 kg of active ingredient of the formula I are introduced into hard gelatine capsules in a conventional manner in such a way that each capsule contains 20 mg of the active ingredient.

30

2002310904 14 Dec 2007

Example H: Ampoules

A solution of 1 kg of active ingredient of the formula I in 60 l of bidistilled water is sterile filtered, transferred into ampoules, lyophilised under sterile conditions and sealed under sterile conditions. Each ampoule contains 10 mg of active

5 ingredient.

Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or

10 step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be


15 taken as an acknowledgment or admission or any form of suggestion that the prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.

2002310904 14 Dec 2007

- 28 -

The claims defining the invention are as follows:

1. Compound of the general formula I



5 in which

A-B-D is $-NR^6-CR^2=N-$, $-N=CR^2-NR^6-$ or $-N=CR^7-CR^8=N-$,

R^1 is Het¹,

R^2 is H, A, cycloalkyl, $-(CH_2)_n-N(R^5)_2$, $-(CH_2)_n-OR^5$, $-(CH_2)_n-Ar$ or $-(CH_2)_n-Het$,

10 R^3 is H, Hal, OH, OA or O- $(CH_2)_n-Ar$,

R^4 is H, A or $-(CH_2)_n-Ar$,

R^5 is H or A,

R^6 , R^7 and R^8 are each, independently of one another, H, A or $-(CH_2)_n-Ar$,

15 R^7 and R^8 together are alternatively alkylene having from 3 to 6 carbon atoms,

A is a linear or branched alkyl group having from 1 to 10 carbon atoms,

20 Ar is phenyl, naphthyl or biphenyl, each of which is unsubstituted or monosubstituted or polysubstituted by Hal, A, OR⁵, N(R⁵)₂, NO₂, CN, COOR⁵, CON(R⁵)₂, NR⁵COR⁵, NR⁵CON(R⁵)₂, NR⁵SO₂A, COR⁵, SO₂NR⁵ or S(O)_mA,

cycloalkyl is cycloalkyl having from 3 to 10 carbon atoms,

25 Hal is F, Cl, Br or I,

Het is a saturated, unsaturated or aromatic monocyclic or bicyclic heterocyclic radical having from 5 to 10 ring

2002310904 14 Dec 2007

- 29 -

members, which may contain from 1 to 4 N and/or from 1 to 4 S and/or from 1 to 4 O atoms, and in which the heterocyclic radical may be monosubstituted, disubstituted or trisubstituted by Hal, A,

5 -[C(R⁵)₂]₀-Ar, -[C(R⁵)₂]₀-cycloalkyl, OR⁵, N(R⁵)₂, NO₂, CN, COOR⁵, CON(R⁵)₂, NR⁵COA, NR⁵CON(R⁵)₂, NR⁵SO₂A, COR⁵, SO₂NR⁵ or S(O)_mA and/or carbonyl oxygen,

10 Het¹ is a saturated, unsaturated or aromatic monocyclic, bicyclic or tricyclic heterocyclic radical having from 5 to 10 ring

members which contains at least 1 N atom and in which the heterocyclic radical may be monosubstituted, disubstituted or trisubstituted by Hal, A, OR⁵, N(R⁵)₂, NO₂, CN and/or carbonyl oxygen,

15 n is 0, 1, 2, 3, 4, 5, 6, 7 or 8,

m is 1 or 2,

o is 0, 1, 2, 3 or 4,

or a physiologically acceptable salt or solvate thereof.

2. Compound of the formula I according to Claim 1, in which R⁴ is
20 hydrogen.

3. Compound of the formula I according to Claim 1 or 2, in which R³ is
hydrogen.

25 4. Compound of the formula I according to any one of Claims 1 to 3, in
which A-B-D is -NR⁶-CR²=N- or -N=CR²=NR⁶, and R⁶ is hydrogen,
and R² is as defined in Claim 1.

30 5. Compound of the formula I according to any one of Claims 1 to 3, in
which A-B-D is -N=CR⁷-CR⁸=N-, and R⁸ is hydrogen, and R⁷ is as
defined in Claim 1.

2002310904 14 Dec 2007

- 30 -


6. Compound of the formula I according to Claim 1 selected from:

- a) 9-(1-azabicyclo[2.2.2]oct-3-yl)-7H-pyrrolo[3,2-f]quinoxaline,
- b) {2-[8-(1-azabicyclo[2.2.2]oct-3-yl)-3,6-dihydroimidazo[4,5-e]indol-2-yl]ethyl}dimethylamine,
- 5 c) 8-(1-azabicyclo[2.2.2]oct-3-yl)-2-(6-methoxy-1H-indol-3-ylmethyl)-3,6-dihydroimidazo[4,5-e]indole,
- d) 8-(1-azabicyclo[2.2.2]oct-3-yl)-2-(2-imidazol-1-ylethyl)-3,6-dihydroimidazo[4,5-e]indole,
- e) 8-(1-azabicyclo[2.2.2]oct-3-yl)-2-pyridin-3-yl-3,6-dihydroimidazo[4,5-e]indole

10 or a physiologically acceptable salt or solvate thereof.

7. Process for the preparation of a compound of the formula I or a salt or solvate thereof according to any one of claims 1 to 6 in which

15 a) A-B-D is $-NR^6-CR^2=N-$ or $-N=CR^2-NR^6-$, or a salt or solvate thereof, by reacting a compound of the formula II



in which R^1 , R^3 and R^4 are as defined in Claims 1 to 3,
with a compound of the formula III

20 $H_2N-CH_2-R^2$ III,

in which


R^2 is as defined in Claim 1,

in the presence of an oxidant,


or

25 b) A-B-D is $-N=CR^7-CR^8=N-$, or a salt or solvate thereof, by reacting
a compound of the formula IV

- 31 -



in which R¹, R³ and R⁴ are as defined in Claims 1 to 3,
with a compound of the formula V



5 in which
R⁷ and R⁸ are as defined in Claim 1,
in the presence of an oxidant,
and/or
a base of the formula I obtained is converted into one of its salts by
10 treatment with an acid.

- 15 8. Compound of the formula I according to any one of Claims 1 to 6 or a physiologically acceptable salt or solvate thereof as a medicament active ingredient.
- 15 9. Compound of the formula I according to any one of Claims 1 to 6 or a physiologically acceptable salt or solvate thereof as a ligand of the nicotinic acetylcholine receptor.
- 20 10. Compound of the formula I according to any one of Claims 1 to 6 or a physiologically acceptable salt or solvate thereof as a serotonergic ligand.
11. A pharmaceutical composition comprising at least one compound of the

formula I according to any one of Claims 1 to 6 and/or a physiologically acceptable salt or solvate thereof.

12. Use of at least one compound of the formula I according to any one of Claims 1 to 6 and/or a physiologically acceptable salt or solvate thereof for the preparation of a medicament.
13. Use of at least one compound of the formula I according to any one of Claims 1 to 6 and/or a physiologically acceptable salt or solvate thereof for the preparation of a medicament for the treatment of disorders in which excitation of the nicotinic acetylcholine receptors results in an improvement in the clinical picture.
14. Use of at least one compound of the formula I according to any one of Claims 1 to 6 and/or a physiologically acceptable salt or solvate thereof for the preparation of a medicament for the prophylaxis or treatment of psychoses, schizophrenia, depression, anxiety states, dementia, Alzheimer's disease, Lewy bodies dementia, neurodegenerative disorders, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, Tourette's syndrome, learning or memory restrictions, bulimia, anorexia nervosa or other eating disorders, compulsive behaviour, premenstrual syndrome, age-induced memory impairment, amelioration of withdrawal symptoms in nicotine dependence, stroke or brain damage by toxic compounds.
15. Use of at least one compound of the formula I according to any one of Claims 1 to 6 and/or a physiologically acceptable salt or solvate thereof for the preparation of a medicament for the treatment of disorders which are characterised by an excess of circulating serotonin or by serotonergic hyperactivity.
16. A method of treating disorders in which excitation of the nicotinic

acetylcholine receptors results in an improvement in the clinical picture comprising administering to a subject in need thereof at least one compound of the formula I as defined in any one of claims 1 to 6 and/or a physiologically acceptable salt or solvate thereof.

5

17. A method of preventing or treating psychoses, schizophrenia, depression, anxiety states, dementia, Alzheimer's disease, Lewy bodies dementia, neurodegenerative disorders, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, Tourette's

10

syndrome, learning or memory restrictions, bulimia, anorexia nervosa or other eating disorders, compulsive behaviour, premenstrual syndrome, age-induced memory impairment, amelioration of withdrawal symptoms in nicotine dependence, stroke or brain damage by toxic compounds comprising administering to a subject in need thereof at least one

15

compound of the formula I as defined in any one of claims 1 to 6 and/or a physiologically acceptable salt or solvate thereof.

18. A method of treating disorders which are characterised by an excess of circulating serotonin or by serotonergic hyperactivity comprising

20

administering to a subject in need thereof at least one compound of the formula I as defined in any one of claims 1 to 6 and/or a physiologically acceptable salt or solvate thereof.

19. Compounds of the general formula I as claimed in claim 1; uses and

25

pharmaceutical compositions thereof; processes for the preparation of compounds of the general formula I as claimed in claim 7; and methods of treatment, substantially as hereinbefore described with reference to the description and examples.